ポスターダウンロード_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Pharmacology service

ゲノム編集

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

資料ダウンロード

ポスターダウンロード

ニュース & PR

世界に通用する跳躍

ニュースリリース

キャンペーン一覧

ウェビナー

発表論文一覧

資料ダウンロード

ポスターダウンロード

製品資料ダウンロード

AACR 2023: In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage

AACR 2023: Novel Humanized CD36 Mouse Model for Therapeutic Studies

AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution

AACR 2023: Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution

PEGS-EU 2022:YH013, A Fully-human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-tumor Efficacy

PEGS-EU 2022:1C3—A Differentiated Non-Blocking Agonist TNFR2 Antibody for Cancer Immunotherapy

PEGS-EU 2022:A Novel TCR-mimic Fully Human Antibodies Discovery Platform

World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors

1 … 5 6 7 8 9 … 11